Seeking Alpha

Four board members forced out at QRxPharma

  • Bowing to pressure from disgruntled institutional shareholders, four members of QRxPharma's (QRXPY -2.4%) BOD resign, including Chairman Dr. Peter Farrell, prior to today's General Meeting of shareholders. The source of the discontent is management's failure to earn FDA approval for its lead product Moxduo, a combo analgesic of morphine and oxycodone. The NDA was filed in November 2013 but received a negative Ad Comm vote on April 22, 2014 and a subsequent thumbs down from the agency.
Comments (1)
  • sheepery
    , contributor
    Comments (2) | Send Message
     
    Well it will be interesting to see where we go from here.
    9 Jul, 11:23 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|